Floatz logo

Pembrolizumab

Leukaemia

Essen Biotechmonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

124 Active assets in the Leukaemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →